SB-121 (Lactobacillus Reuteri) safety and tolerability in **autistic disorder** assessed in Phase I crossover trial.
28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder
Abstract
SB-121 (Lactobacillus Reuteri) safety and tolerability in autistic disorder subjects (15-45 years) are the primary focus of a 28-day daily-dose Phase I crossover trial.
